BEAM-302: Beam’s lead genetic disease program is BEAM-302, a potentially best-in-class liver-targeting LNP formulation of base editing reagents designed to correct the PiZ allele, the most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback